Kiniksa Pharmaceuticals International, plc SEC filings KNSA
Kiniksa Pharmaceuticals International, plc has 776 filings in SEC EDGAR's recent list, going back to Feb 27, 2018. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 27, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 15-15D/A | Filing | Jul 23, 2024 | — |
| EFFECT | Filing | Jul 3, 2024 | — |
| EFFECT | Filing | Jul 3, 2024 | — |
| CORRESP | Letter to the SEC | Jul 2, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2024 | — |
| EFFECT | Filing | Jun 28, 2024 | — |
| 15-15D | Filing | Jun 28, 2024 | — |
| 8-K12B | Filing | Jun 28, 2024 | Jun 27, 2024 |
| UPLOAD | Letter from the SEC | Jan 2, 2024 | — |
| CORRESP | Letter to the SEC | Dec 8, 2023 | — |
| CORRESP | Letter to the SEC | Nov 21, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2023 | — |
| EFFECT | Filing | May 17, 2022 | — |
| EFFECT | Filing | May 17, 2022 | — |
| CORRESP | Letter to the SEC | May 13, 2022 | — |
| CORRESP | Letter to the SEC | May 13, 2022 | — |
| UPLOAD | Letter from the SEC | May 13, 2022 | — |
| UPLOAD | Letter from the SEC | May 13, 2022 | — |
| CT ORDER | Filing | Jan 19, 2022 | — |
| CT ORDER | Filing | Feb 9, 2021 | — |
| D/A | Filing | Nov 23, 2020 | — |
| EFFECT | Filing | Sep 21, 2020 | — |
| CORRESP | Letter to the SEC | Sep 17, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2020 | — |
| EFFECT | Filing | Jun 4, 2020 | — |
| CORRESP | Letter to the SEC | Jun 2, 2020 | — |
| UPLOAD | Letter from the SEC | May 29, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 19, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 7, 2020 | — |
| D/A | Filing | Jul 11, 2019 | — |
| EFFECT | Filing | Jun 10, 2019 | — |
| CORRESP | Letter to the SEC | Jun 6, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2019 | — |
| D | Filing | Apr 4, 2019 | — |
| EFFECT | Filing | Jan 30, 2019 | — |
| DRS | Filing | Dec 13, 2018 | — |
| CT ORDER | Filing | May 25, 2018 | — |
| EFFECT | Filing | May 23, 2018 | — |
| CERT | Filing | May 23, 2018 | — |
| CORRESP | Letter to the SEC | May 21, 2018 | — |
| CORRESP | Letter to the SEC | May 21, 2018 | — |
| CORRESP | Letter to the SEC | May 18, 2018 | — |
| CORRESP | Letter to the SEC | May 17, 2018 | — |
| UPLOAD | Letter from the SEC | May 16, 2018 | — |
| 8-A12B | Filing | May 14, 2018 | — |
| CORRESP | Letter to the SEC | May 8, 2018 | — |
| UPLOAD | Letter from the SEC | May 4, 2018 | — |
| CORRESP | Letter to the SEC | May 2, 2018 | — |
| CORRESP | Letter to the SEC | Apr 27, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2018 | — |
| DRSLTR | Filing | Apr 6, 2018 | — |
| DRS/A | Filing | Apr 6, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2018 | — |
| DRS | Filing | Feb 27, 2018 | — |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KNSA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1730430
- Former names
- Kiniksa Pharmaceuticals, Ltd. (until Jun 28, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.